New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
10:00 EDTTHLD, PXD, LINE, BIIB, YUM, RPRX, MPLX, INFI, BRFS, WAIR, RLGY, LNCO, CELG, BEAVOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: BE Aerospace (BEAV) initiated with an Outperform at Imperial Capital... BRF Brasil Foods (BRFS) initiated with a Buy at Citigroup... Biogen (BIIB) initiated with a Buy at Brean Capital... Celgene (CELG) initiated with a Buy at Brean Capital... Infinity Pharmaceuticals (INFI) initiated with an Outperform at RBC Capital... LINN Energy (LINE) initiated with a Neutral at Goldman... LINN Energy (LINE) initiated with an Outperform at RW Baird... LinnCo (LNCO) initiated with a Buy at UBS... LinnCo (LNCO) initiated with a Neutral at Credit Suisse... MPLX (MPLX) initiated with a Buy at Citigroup... Matrix Service (MTRX) initiated with a Buy at DA Davidson... Pioneer Natural (PXD) initiated with a Buy at Citigroup... Realogy (RLGY) initiated with a Neutral at Citigroup... Repros Therapeutics (RPRX) initiated with a Buy at Roth Capital... Threshold Pharmaceuticals (THLD) initiated with a Buy at Brean Capital... Wesco Aircraft (WAIR) initiated with an In-Line at Imperial Capital... Yum! Brands (YUM) initiated with an Outperform at Macquarie
News For BEAV;BRFS;BIIB;CELG;INFI;LINE;LNCO;MPLX;PXD;RLGY;RPRX;THLD;WAIR;YUM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 20, 2014
16:16 EDTYUMYum! Brands authorizes up to $1B in share repurchases
Yum! Brands board authorized the company to repurchase up to $1B in additional shares of common stock. The $1B in additional share repurchases of the company’s outstanding common stock is authorized through May 31, 2016.
16:13 EDTWAIRWesco Aircraft announces retirement of CFO Gregory A. Hann
Subscribe for More Information
16:12 EDTWAIRWesco Aircraft sees FY15 adjusted EPS $1.30-$1.40, consensus $1.55
Sees FY15 revenue $1.625B-$1.675B, consensus $1.68B. The company also expects free cash flow of $100M-$120M in fiscal 2015.
16:10 EDTWAIRWesco Aircraft reports Q4 adjusted EPS 30c, consensus 37c
Subscribe for More Information
10:02 EDTYUMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:26 EDTYUMYum! Brands upgraded to Buy at Janney Capital
Subscribe for More Information
06:06 EDTYUMYum! Brands upgraded to Buy from Neutral at Janney Capital
Subscribe for More Information
November 19, 2014
09:39 EDTCELGCelgene management to meet with ISI Group
Subscribe for More Information
07:52 EDTINFI, BIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 18, 2014
12:46 EDTRPRXRepros Therapeutics volatility at low end of six-month range
Repros Therapeutics overall option implied volatility of 102 compares to its 26-week average of 111 according to Track Data, suggesting decreasing price movement.
07:34 EDTCELGCelgene presents long-term OTEZLA data at ACR/ARHP meeting
Celgene announced that results from long-term efficacy and safety analyses of OTEZLA from the open-label phase of two PALACE phase III clinical trials were presented at the 2014 American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in Boston. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4, approved by the U.S. FDA for the treatment of adult patients with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In PALACE 1, 84 percent of patients who completed one year of 30 mg twice daily therapy continued to receive OTEZLA at two years. Improvements in efficacy measures observed at 52 weeks were sustained through 104 weeks of treatment. At week 104, among patients receiving OTEZLA 30 mg twice daily, the ACR20 response rate was 65.3 percent. ACR50 and 70 response rates were 34.0 percent and 19.6 percent, respectively, at week 104. Similar findings were observed in PALACE 4. In this trial, nearly 84 percent of DMARD-naïve patients who completed one year of OTEZLA 30 mg twice daily monotherapy continued to receive OTEZLA at two years. At week 104, among patients treated with OTEZLA 30 mg twice daily monotherapy, an ACR20, 50 and 70 response was reached by 61.4 percent, 40.7 percent and 19.2 percent of patients, respectively. In both PALACE 1 and PALACE 4, changes in other efficacy measures—including the HAQ-DI, which assesses improvements in physical function, and swollen and tender joint counts—were also generally sustained between weeks 52 and 104 with continued OTEZLA treatment. In PALACE 4, treatment with OTEZLA in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in improvements in enthesitis and dactylitis that were sustained through 104 weeks of treatment.
November 17, 2014
07:16 EDTCELGMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
07:05 EDTTHLDThreshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim data
Threshold Pharmaceuticals announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab for the treatment of glioblastoma, or GBM, the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only FDA-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months. In addition, the FDA, through its Office of Orphan Product Development, recently awarded Dr. Brenner a grant for a Phase 2 clinical trial of TH-302 for the treatment of GBM. His is one of 15 grants the FDA awarded in 2014 in order to boost the development of medical device, drug, and biological products for patients with rare diseases. According to the FDA, the grants are for clinical studies on safety and/or effectiveness of products that could either result in, or substantially contribute to, approval of the products.
November 14, 2014
18:05 EDTBEAVRelational Investors gives quarterly update on stakes
NEW STAKES: None. INCREASED STAKES: None. DECREASED STAKES: Mondelez (MDLZ), Manitowoc (MTW), Clean Harbors (CLH), and Hologic (HOLX). LIQUIDATED STAKES: Ingersoll-Rand (IR), B/E Aerospace (BEAV), Timken (TKR), Hess (HES), and NXP Semiconductors (NXPI).
17:07 EDTCELGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
07:14 EDTCELGAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
10:44 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
07:10 EDTTHLDSociety for NeuroOncology to hold a meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use